-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: UK Dementia Research Institute
Dementia Moonshot Report: Research Priorities and Costs (Alzheimer’s Research UK)
Summary Alzheimer’s Research UK (ARUK) have released a brief report on six research priorities, which are: Achieving earlier detection of diseases which may cause dementia, (ideally by 10-15 years), to enhance development of new treatments / interventions for people most … Continue reading →
Posted in Alzheimer’s Research UK, Charitable Bodies, Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Accelerating Alzheimer's Research and Drug Development, Accelerating Detection of Disease, Accelerating Detection of Disease (ADD) Challenge, Accelerating Detection of Disease Programme, Alzheimer's and Dementia: Translational Research and Clinical Interventions (TRCI), Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK’s Dementia Attitudes Monitor, Alzheimer’s Research UK’s Drug Discovery Alliance, Awareness, Awareness Raising, Benefits of Detection and Early Intervention, Benefits of Early Detection, Biomarker Development, Biomarkers, Brain Health Clinics, Charity Research Support Fund, Cognitive Function and Ageing Study II, Cross-Funder Review, Dementia Access Taskforce, Dementia Consortium, Dementia Moonshot, Dementia Prevalence, Dementia Prevention, Dementia Research, Dementia Research and Drug Development, Dementia Research Funding, Dementia Research Priorities, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dementia Translational Medicines Accelerator, Dementia: Prevalence and Detection, Dementias Platform UK, DPUK: Dementias Platform UK, Dr Helen Beaumont: Alzheimer’s Research UK Champion, Drug Development for Alzheimer's Disease, Drug Discovery Alliance, Drug Discovery Institutes, Drug Target Validation, Early Detection of Neurodegenerative Diseases, Economic Impact of Dementia, Global Impact of Dementia, Global Leadership, Government Research Funding, Grand Challenge on Artificial Intelligence and Data, Helen Stokes-Lampard: Chair of RCGP, Hilary Evans: Chief Executive of Alzheimer’s Research UK, Impact of Dementia, Impact of Dementia (Statistics), Impact of Dementia in UK, Life Sciences Industrial Strategy, Life-Changing Treatment for Dementia by 2025 (Moonshot Aim), Medical Research Charities, Mike Gooley Trailfinders Charity Prevention and Risk Reduction Fund, Modifiable Risk Factors, Multi-Morbidities, Multi-Morbidity, No Time to Lose: An Action Plan for Dementia (ARUK), Participation in Research, Patient Involvement in Research, Potential Drug Targets, Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Professor Jamie Waterall: National Lead for Cardiovascular Disease at Public Health England, Professor Tara Spires-Jones: Alzheimer’s Research UK Grant Review Board, Research Funding, Research Priorities and Funding / Costs, Research Priorities and Networks, Social and Economic Impact of Dementia, Social and Economic Impact of Dementia in UK, Target Robustness Programme, Translational Medicines, Translational Research, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Health Research Funding
|
Leave a comment
The State of Dementia Research Globally: World Alzheimer Report 2018 (Alzheimer’s Disease International)
Summary The World Alzheimer Report 2018, entitled “The state of the art of dementia research: New frontiers”, reviews developments in dementia research, without glossing-over the absence of significant disease-modifying pharmacological treatment breakthroughs for around 20 years. This report examines wide-ranging … Continue reading →
Posted in Acute Hospitals, Alzheimer’s Disease International (ADI), Charitable Bodies, Community Care, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Person-Centred Care, Quick Insights, Standards, Statistics, UK, Universal Interest
|
Tagged ADI’s World Alzheimer Reports, Alireza Atri: Director of Banner Sun Health Research Institute, Alzheimer's Research, Alzheimer’s Disease International (ADI), Alzheimer’s Disease Research Unit: McGill Centre for Studies in Ageing (Canada), Alzheimer’s Prevention Initiative: Banner Health (USA), Alzheimer’s Prevention Initiative: Banner Sun Health Research Institute, Banner Sun Health Research Institute, Burden of Alzheimer’s Disease, Burden of Dementia (Statistics), Centre for Dementia Prevention: University of Edinburgh, Dementia as Cause of Death, Dementia Awareness, Dementia Awareness Raising, Dementia Collaborative Research Centre: University of New South Wales, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Prevention, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies for Dementia, Disease-Modifying Treatments for Dementia, Dr Christopher Chen: Director of Memory Ageing and Cognition Centre at National University Health System: Singapore, Dr Doug Brown: Chief Executive Officer of British Society for Immunology, Dr Doug Brown: Former Chief Policy and Research Officer at Alzheimer’s Society, Dr Jennifer Bute: Dementia Alliance International (DAI), Dr Kenji Toba: President of National Centre for Geriatrics and Gerontology (Obu), Dr Maria Carrillo: Chief Science Officer at Alzheimer’s Association US, Dr Miia Kivipelto: Karolinska Institute, Dr Miia Kivipelto: Karolinska University Hospital (Stockholm), Dr Rachelle Doody: Global Head of Neurodegeneration at Roche, Dr Serge Gauthier: Director of Alzheimer’s Disease Research Unit at McGill Centre for Studies in Ageing in Canada, Drug Trials Failure Rate, Epidemiology, Epidemiology and Statistics, Francesca Colombo: Organisation for Economic Co-operation and Development (OECD), Fundación para la Lucha contra las Enfermedades Neurológicas (FLENI), Glenn Rees: Chairman of Alzheimer’s Disease International, Glenn Rees: Former CEO of Alzheimer’s Australia, Global Burden of Dementia, Global Dementia Discovery Fund (2015), Identification and Intervention for Dementia in Elderly Africans (IDEA Group), Jeff Cummings: Director of Cleveland Clinic at Lou Ruvo Centre for Brain Health, Kate Bingham: SV Health Managers, King’s College London, Market Failure (Dementia Research and Drug Development), Martin Knapp: London School of Economics, Memory Ageing and Cognition Centre at National University Health System: Singapore, Memory Ageing and Cognition Centre: National University Health System (Singapore), National Centre for Geriatrics and Gerontology (Japan), Optima (University of Oxford’s Dementia Research Project), OPTIMA Cohort (Oxford Project to Investigate Memory and Ageing), Oxford Project to Investigate Memory and Ageing (OPTIMA Study), Paola Barbarino: Alzheimer’s Disease International, Prevention, Prevention Agenda, Prevention of Future Dementia Cases by Increasing Knowledge of Risk and Protective Factors, Professor Adesola Ogunniyi: University College Hospital (Ibadan), Professor Bart De Strooper: Director of the UK Dementia Research Institute (UK DRI), Professor Craig Ritchie: Chair of Psychiatry of Ageing at University of Edinburgh, Professor Craig Ritchie: Director at Centre for Dementia Prevention, Professor Gordon Wilcock: Co-founder of Alzheimer’s Society UK, Professor Gordon Wilcock: Emeritus Professor of Geratology at University of Oxford, Professor Henry Brodaty: Director of Dementia Collaborative Research Centre at University of New South Wales, Professor Martin Knapp: Director of the Personal Social Services Research Unit at the London School of Economics and Political Science (LSE), Professor Martin Prince: Assistant Principal for Global Health at King’s College London, Research Networks, Ricardo Allegri: Head of Cognitive Neurology Neuropsychology and Neuropsychiatry at Fundación para la Lucha contra las Enfermedades Neurológicas (FLENI), Risk and Protective Factors, State of the Art of Dementia Research: New Frontiers (World Alzheimer Report 2018), Supporting People Affected by Dementia, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Dementia Research Institute at UCL, University College Hospital (Ibadan Nigeria), World Alzheimer Report, World Alzheimer Report 2018: State of the Art of Dementia Research, World Alzheimer Report: 2018, World Alzheimer’s Day 2018
|
Leave a comment
Review of Assistive Technology (NIHR / BBC News)
Summary An National Institute for Health Research (NIHR) funded themed review on the application of assistive technologies covers many interventions, including technology in the home, use of remote monitoring systems and the design of better environments for older people. Full … Continue reading →
Posted in Assistive Technology, Commissioning, Community Care, Falls Prevention, For Carers (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, Management of Condition, National, NIHR, Non-Pharmacological Treatments, Person-Centred Care, Personalisation, Quick Insights, Telecare, Telehealth, UK, Universal Interest
|
Tagged AAL-WELL: Ambient Assistive Living Technologies for Wellness, Advancing Knowledge of Telecare for Independence and Vitality in Later Life Project (AKTIVE), Ambient Assisted Living (AAL), ARCHIE Framework for Effective Telehealth and Telecare Services, Assistive Technology and Telecare to Maintain Independent Living At Home for People with Dementia: ATTILA Trial, Assistive Technology to Avoid Hospital Admissions, ATTILA Trial: Assistive Technology and Telecare to Maintain Independent Living At Home, Barriers to Mainstreaming Assistive Living Technologies (MALT), Barriers to Telecare Adoption, Bathing Adaptations in Homes of Older Adults: BATHOUT Trial, BBC Health News, Benefits of Remote Monitoring, BESiDE: Built Environment for Social Inclusion in Digital Economy, Care at Home Using Intelligent Robotic Omni-Functional Nodes (CHIRON), Care Research and Technology Centre: Imperial College London, Co-Motion: Mobility and Wellbeing in Later Life, COMODAL: COnsumer MODels for Assisted Living, CompanionAble: Integrated Cognitive Assistive and Domotic Companion Robotic Systems for Ability and Security, Compensating for Cortical Visual Dysfunction in Alzheimer’s Disease, Computer Interactive Reminiscence and Conversation Aid Groups, Consumer Models for Assisted Living (COMODAL), Dementia Friendly Architecture: Reducing Spatial Disorientation in Dementia Care Homes, Dementia-Friendly Design, Dementia-Friendly Homes, Dementia-Friendly Housing, Dementia-Friendly Specifications, Design for Ageing Well: Improving the Quality of Life for Ageing Population Using a Technology Enabled Garment System, Design for People with Dementia, Designing for Wellbeing in Environments for Later Life (DWELL), Ecaalyx: Enhanced Complete Ambient Assisted Living Experiment, Engagement and Long Life, Ethical Frameworks FOR Telecare Technologies (EFORTT), Future Bathroom: Study of User-Centred Design Principles Affecting Usability Safety and Satisfaction in Bathrooms for People With Disabilities, Health Monitoring, Healthy Dementia Home (Professor David Sharp), Healthy Dementia Homes (UK Dementia Research Institute at Imperial College London), Home Monitoring, Imperial College London, Information Technology to Avoid Hospital Admissions, Kitchen Living in Later Life, Lifelong Health and Wellbeing Cross-Council Programme (LHWCP), Location and Tracking Devices, Mainstreaming on Ambient Intelligence (MonAMI) Project, NANA: Novel Assessment of Nutrition and Ageing, National Institute for Health Research (NIHR), New Dynamics of Ageing Programme (NDAP), NIHR CLAHRC, NIHR DC: NIHR Dissemination Centre, NIHR Invention for Innovation (NIHR i4i), NIHR School for Social Care Research (NIHR SSCR), NOCTURNAL: Night Optimised Care Technology for UserRs Needing Assisted Lifestyles, Non-Invasive Telemonitoring, Older People’s Living Environments (EVOLVE), Professor David Sharp: UK Dementia Research Institute at Imperial College London, Project About Loneliness and Social Networks (PALS) Study, Putting Life in Years (PLINY): Telephone Friendship Groups Research Study, Ready Steady Go: Telehealth Implementation Toolkit, Remote Monitoring Systems, RoboSafe: Trustworthy Robotic Assistants, Seamless User-Centred Proactive Provision of Risk-Stratified Treatment for Heart Failure (SUPPORT-HF), SOPRANO: Service Oriented Programmable Smart Environments for Older Europeans, Supporting Safe Walking for People with Dementia, Technology Platform for Assisted Living of People with Dementia and Their Carers, Technology Strategy Board (TSB), Telehealth, Telehealth (Remote Monitoring), Telemonitoring, TiKL: Transitions in Kitchen Living, TOTALCARE: Digital Healthcare Framework Integrating Secure Personal Monitoring With P2P (Peer to Peer) Medical Condition Community Support Focused on Ageing and Obesity, Tracking and Monitoring Technology to Avoid Hospital Admissions, TSB Assisted Living Platform, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Dementia Research Institute: Imperial College London, USEFIL: Unobtrusive Smart Environments For Independent Living, UTOPIA Project: Using Telecare for Older People in Adult Social Care
|
Leave a comment
Dementia Researchers Recognised and Rewarded (BBC News / Lundbeck Foundation)
Summary Four dementia researchers share the 2018 (€1 million Euro) Brain Prize (bestowed by the Lundbeck Foundation), in recognition of their joint work on the underlying neuropathological mechanisms thought to cause of Alzheimer’s Disease. Full Text Link Reference Roberts, M. … Continue reading →
Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, UK, Universal Interest
|
Tagged Abnormal Proteins, Abnormal Proteins (Tau), Alzheimer’s Disease, Alzheimer’s Disease and Dementia, Alzheimer’s Disease: Causes, Amyloid Beta Protein, Amyloid Cascade Hypothesis, Amyloid Proteins, Amyloid-β Protein, Annual €1 Million Brain Prize, Apolipoprotein E (APOE) Gene, Asymptomatic Alzheimer’s Disease, Cambridge University, Dementia Research, Dementia Research Careers, Dementia Research Funding, Genetic Research, Germany, Global Context, Global Dementia Research, Global Outlook, β-Amyloid Precursor Protein (APP), Lundbeck Foundation (Denmark), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuropathologic Disorders, Neuropathology, Pathophysiological Processes in Alzheimer’s Disease, Professor Bart De Strooper: Director of the UK Dementia Research Institute (UK DRI), Professor Christian Haass, Professor John Hardy, Professor Michael Goedert, The Brain Prize (Lundbeck Foundation), UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Dementia Research Institute at UCL, University College London, University of Munich
|
Leave a comment
Research Towards a World Without Dementia: Marking World Alzheimer’s Day / World Alzheimer’s Month 2017 (Alzheimer’s Disease International / Department of Health)
Summary Information is available from Alzheimer’s Disease International (ADI) concerning World Alzheimer’s Month (September) and World Alzheimer’s Day 2017, which was on September 21st 2017. The theme for this year’s World Alzheimer’s Month campaign is again “Remember Me”. The UK … Continue reading →
Posted in Charitable Bodies, Commissioning, Department of Health, Diagnosis, In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest
|
Tagged 70th World Health Assembly Adopted Global Action Plan on Dementia, Ageing Population, Awareness, Awareness Campaigns, Awareness Raising, Carey Mulligan, Carey Mulligan: UK Global Dementia Friends Ambassador, Collaborative Research, Collaborative Working, Community and Voluntary Sector, Dementia Awareness Campaigns, Dementia Awareness Raising, Dementia Friends, Dementia Friends Programme, Dementia Research, Dementia Research Institute (DRI), Dementia-Friendly Communities, Dementia-Friendly Environments, Dementia-Friendly Organisations, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, First G8 Dementia Summit, Former Health Secretary Jeremy Hunt, G8 Dementia Summit, G8 Dementia Summit Declaration, G8 Dementia Summit: Global Action Against Dementia, Global Action Against Dementia, Global Action Plan on Dementia, Global Alzheimer’s and Dementia Action Alliance, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Context, Global Dementia Friends Ambassadors, Global Leadership, International Collaborations, International Dementia Research, Leadership for Compassionate Care, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Partnership Working, Reducing Stigma, Research and Development, Research and Innovation, Research Commitment, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, Stigma of Dementia, Stigma-Free Environments, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), Voluntary Organisations, WHO Global Action Plan on the Public Health Response to Dementia 2017-2025, World Alzheimer's Month 2017 (Remember Me), World Alzheimer’s Day 2017, World Alzheimer’s Month 2017, Yuichiro Miura: Japan’s Dementia Supporters Ambassador
|
Leave a comment
Grounds for Cautious Optimism Regarding Two Drugs Re-Purposed for Neurodegenerative Diseases? (BBC News / MRC / NHS Choices / Brain)
Summary Animal research, involving mice, has indicated promising results for the potential of two re-purposed drugs in helping to slow or halt the progression of a number of neurodegenerative brain diseases, including dementia. “The best known drug of the pair … Continue reading →
Posted in Animal Studies, BBC News, For Researchers (mostly), In the News, National, NHS Digital (Previously NHS Choices), Parkinson's Disease, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Abnormal Prion Protein, Alzheimer's Disease, Alzheimer's Research UK, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Drug Discovery Institute, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Autoimmune Attacks, Autoimmune Cell Defences, BBC Health News, Behind the Headlines, Brain (Journal), Centre for Analytical Bioscience: University of Nottingham, CJD, Creutzfeldt-Jakob Disease, Creuzfeldt Jacob Disease (CJD), Department of Clinical Neurosciences: University of Cambridge, Dibenzoylmethane, Dibenzoylmethane (DBM): Potential Anti-Cancer Drug, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr David Dexter: Parkinson's UK, Dr Doug Brown: Director of Research and Development at Alzheimer's Society, Drug Discovery Programmes, eIF2a-P-Mediated Translational Repression (Pathway of Neurodegeneration), Frontotemporal Dementia (FTD), Huntingtin Protein, Huntington’s Disease, α-Synuclein, α-Synuclein Aggregation, Lentivirally Mediated RNA Interference (RNAi), Medical Research Council (MRC), Medical Research Council (UK), Medical Research Council Toxicology Unit: University of Leicester, Medical Research Council’s (MRC) Toxicology Unit, Microscopic Worms, Misfolded Prion Protein (PrP), Misfolded Proteins, Motor Neurone Disease (MND), MRC Toxicology Unit: University of Leicester, MRC: Medical Research Council, Multiple Sclerosis, National Institute for Neurological Disorders and Stroke, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuronal Loss, Neuroprotection, Parkinson's, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Prion Diseases, Prion Protein (PrP(C)), Prion-Infected Mice, Prof. Giovanna Mallucci, Professor Giovanna Mallucci: Associate Drector of UK Dementia Research Institute, Protein Misfolding, Rare Prion Diseases, Repurposing of Drugs, Synucleinopathy, Tau, Tau Protein, Tauopathy, Translational Research, Transmissible Spongiform Encephalopathies, Trazodone, Trazodone Hydrochloride (Antidepressant), UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), Unfolded Protein Response (UPR), University of Cambridge, University of Leicester, University of Nottingham, Worms: C. elegans
|
Leave a comment
Future Director of the UK Dementia Research Institute (MRC / Guardian / JAMA Neurology)
Summary Professor Bart De Strooper has been appointed as the Director of the UK Dementia Research Institute (UK DRI). Prof. De Strooper currently leads the Laboratory for the Research of Neurodegenerative Diseases at the University of Leuven and is scientific … Continue reading →
Posted in For Researchers (mostly), In the News, International, Models of Dementia Care, National, Quick Insights, UK, Universal Interest
|
Tagged Ageing Population, Belgium, Biomarker Development, Biomarkers, Biomarkers Research Programmes, Brain Imaging, Dementia and Alzheimer's Disease: Leading Cause of Death in 2015, Dementia Challenge 2020, Dementia Research, Dementia Research Careers, Dementia Research Institute (DRI), Dementia Research: Roadmap for the Next Decade, Department of Neuroscience: Mayo Clinic Florida, Diagnostic Imaging, Diagnostics, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, Environmental Risk Factors, Epidemiology, G8 Dementia Summit Declaration, Genetics, Global Action Against Dementia, Global Context, Global Leadership, Guardian, Guardian (Newspaper), International Dementia Research, International Dementia Research Inventories, JAMA Neurology, Jo Johnson: Universities and Science Minister, Johns Hopkins University, Laboratory for the Research of Neurodegenerative Diseases: University of Leuven, Laboratory of Neurogenetics: National Institute on Aging, Lifestyle Risk Factors, Mayo Clinic Florida, Medical Research Council (MRC), Medical Research Council (UK), Michael Arthur: UCL President and Provost Professor, MRC: Medical Research Council, National Institutes of Health (NIH), National Institutes of Health (US), National Institutes of Health / National Institutes on Aging, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neuroimaging of Dementia, Neurology, Neuromuscular Diseases Research Section: National Institute on Aging, Neuroscience, Overlapping Risk Factors, Potential Drug Targets, Preclinical Biomarkers and Dementia, Professor Bart De Strooper: Director of the UK Dementia Research Institute (UK DRI), Recruitment of Research Leaders / Rising Stars, Research and Development, Research and Innovation, Research Commitment, Sir John Savill: Chief Executive of the Medical Research Council, UCL DRI Hub, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), United States, University College London (UCL), University of Leuven, US National Institutes of Health, US National Institutes of Health (NIH), USA, VIB (Belgium), VIB-K.U.Leuven
|
Leave a comment
MRC DRI Momentum Awards £4.3 Million For UK Dementia Research (MRC)
Summary Momentum Awards, which support the UK Dementia Research Institute (DRI). Today’s announcement involves six universities being awarded £4.3 million from the MRC to help develop UK-based dementia research. Judging from the press release, there appears to be a serious … Continue reading →
Posted in Commissioning, For Researchers (mostly), In the News, National, Quick Insights, UK, Universal Interest
|
Tagged Autism, Autism Spectrum Disorder (ASD), Biomarkers, Biomarkers Research Programmes, Bioscience Careers, Cardiff University, Computational Approaches to Discovery of Behavioural Signatures, Cross-Disciplinary Interfaces Exploring Emerging Scientific Opportunities, Dementia Research, Dementia Research Careers, Dementia Research Institute (DRI), Dr Kathryn Adcock: Head of Neurosciences and Mental Health at MRC, Epilepsy, Frontiers in Neuroscience, High Risk-High Payoff Research Projects (sic) [For Whom?], Human Brain Cell Types, Immune Pathways and Stem Cell (iPSC) Models of Neurodegenerative Disease, Institute of Psychiatry Psychology and Neuroscience (IoPPN), Kings College London, Maurice Wohl Clinical Neuroscience Institute, Momentum Awards, MRC Centre for Neurodevelopmental Disorders (King’s College London), MRC DRI Momentum Awards, MRC: Medical Research Council, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neurodevelopmental Disorders: Abnormal Brain Development, Neuroinflammation, Neuroinflammation Research Cluster, Neuroscience, Neurovascular Dysfunction, Potential Drug Targets, Professor Oscar Marín: Director of Department of Developmental Neurobiology at Institute of Psychiatry Psychology and Neuroscience (IoPPN), Proteostasis, Proteostasis Dysfunction, Pump-Priming (Dementia Research), Recruitment of Research Leaders / Rising Stars, Research and Development, Research and Innovation, Research Careers, Research Commitment, Research Culture, Research Funding, Schizophrenia, Sensor Platform for Healthcare in a Residential Environment (SPHERE), Signalling Pathways, Treatment and Prevention Targets, UK Dementia Research Institute, University of Bristol, University of Edinburgh, University of Manchester, University of Oxford
|
Leave a comment
New Drugs for Dementia (POST Note PN 535)
Summary The Parliamentary Office of Science and Technology (POST) has produced a briefing outlining some of the challenges in developing new drugs for dementia, explained in the context of ongoing UK and international research programmes. There is an extensive bibliography, … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Academic Institutes in the UK, Academy of Social Sciences, Aducanumab (Biogen), Alzheimer’s Association, Alzheimer’s Research UK’s Drug Discovery Alliance, Behavioural and Psychological Symptoms of Dementia (BPSD), Big Data, Big Data Funding and Research, Big Pharma, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, British Psychological Society (BPS), Co-ordination and Data Analytics, Cognitive Health in Ageing Register for Investigations, Collaborative Projects, Collaborative Research, Dementia Consortium, Dementia Risk Prevention, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), DPUK: Dementias Platform UK, Drug Discovery Alliance, Drug Licensing Approval, Drugs for BPSD, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, EAMS: Early Access to Medicines Scheme, Early Access to Medicines Scheme, Effective Non-Drug Interventions, Etanercept, European Prevention of Alzheimer's Dementia Consortium (EPAD), European Prevention of Alzheimer’s Dementia Consortium, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Join Dementia Research, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, New Drugs for Dementia (POST Note PN 535), NIHR Clinical Research Network, Observations & Trials in Dementia Research, Parliament, Parliamentary Office of Science & Technology, Parliamentary Office of Science & Technology (POST), Participation in Research, Patient Access to New Drugs, Pharmaceutical Industry, Pioglitazone, POST: Parliamentary Office of Science & Technology, Pre-Symptomatic Diagnosis of Dementia, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Prevention, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Solanezumab (Eli Lilly), Symptom-Modifying Drugs for Dementia, UK Dementia Research Institute, UK Parliament, UK Patient Recruitment Initiatives, Verubecestat (Merck), Well-Being and Health for People With Dementia (WHELD) Program
|
Leave a comment
Further Funding for the Dementia Research Institute (Gov UK / MRC / Alzheimer’s Society / ARUK)
Summary Additional partnership funding has been announced for Dementia Research Institute (DRI). The Alzheimer’s Society and Alzheimer’s Research UK have each committed £50 million towards supporting the work of the Institute, making the total commitment to date around £250 million … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Charitable Bodies, Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK’s Drug Discovery Alliance, ARUK: Alzheimer’s Research UK, Challenge on Dementia (David Cameron), Challenge on Dementia 2020, Cross-Sector Partnerships, David Cameron, Dementia Research, Dementia Research Careers, Dementia Research Funding, Dementia Research Institute (DRI), Dementia Research: UK Impact, Dementia Risk Reduction, Department for Business Innovation and Skills, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Alliance, Drug Discovery Programmes, Global Action Against Dementia, Global Context, Global Dementia Discovery Fund (2015), Global Dementia Research, Global Leadership, Global Outlook, Hilary Evans: Chief Executive of Alzheimer’s Research UK, International Dementia Research, Jeremy Hughes CBE: Chief Executive of the Alzheimer’s Society, Jo Johnson MP, Jo Johnson: Universities and Science Minister, Living Well with Dementia Research, Medical Research Council (MRC), Medical Research Council (UK), MRC: Medical Research Council, Neurodegeneration, Neurodegenerative Disease Research, Partnership and Collaboration, Partnership Working, Prime Minister’s Challenge On Dementia 2020, Promisary Science, Public Health Strategies, Research and Development, Research and Innovation, Research Commitment, Research Funding, Sir John Savill: Chief Executive of the Medical Research Council, UK Dementia Research Institute
|
Leave a comment